Status:
WITHDRAWN
Progressive Open Angle Glaucoma (OAG) and Ocular Blood Flow
Lead Sponsor:
Medical University of Vienna
Conditions:
Open Angle Glaucoma
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess the correlation of vascular parameters, including genetic factors as well as ocular blood flow parameters against the progression rate of glaucomatous damage in ...
Detailed Description
Glaucoma is one of the most common causes of blindness in the industrialized nations. For a long time glaucoma has been defined as a disease in which high intraocular pressure (IOP) leads to irreversi...
Eligibility Criteria
Inclusion
- Men and women over 40 years
- Unilateral or bilateral primary open angle glaucoma (POAG) or normal tension glaucoma (NTG) with visual defect, marked by an AGIS score (1994; 1. Study design and methods and baseline characteristics of study patient) of at least 1 but not more than 16 at the screening visit
- At least 3 reliable visual field tests in the eye that will be studied
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Best-corrected visual acuity of 20/40 or better, spherical refraction within ± 3.0 diopters and cylinder correction within ± 3.0 diopters
Exclusion
- Evidence of secondary glaucoma, pseudoexfoliation, pigmentary dispersion
- Any form of retinal or neuroophthalmological disease that could result in visual field defects.
- Mean IOP \> 30 mmHg, or any IOP \> 35 mmHg in at least one eye
- History of acute angle closure
- Closed or barely open anterior chamber angle
- Topical or systemical/oral therapy with steroids
- Standard deviation of visual field testing \> 10
- Ocular inflammation or infection within the last three months
- Intraocular surgery or argon laser trabeculoplasty within the last six months
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- Ametropia \> 3 dpt
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00912470
Start Date
May 1 2007
End Date
November 1 2014
Last Update
November 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Pharmacology
Vienna, Austria, 1090